PTPI
Petros
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
EPS Beats Expectation
Revenue Below Expectations
Revenue Keeps Dropping
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About PTPI
Petros Pharmaceuticals, Inc.
A leading provider of therapeutics for men's health
1185 Avenue of the Americas, 3rd Floor, New York, New York 10036
--
Petros Pharmaceuticals, Inc., was originally incorporated on May 14, 2020 under the General Corporation Law. Petros is committed to becoming the world's leading men's health company by identifying, developing, acquiring and commercializing innovative therapies for men's health problems, including but not limited to ED, endothelial dysfunction, psychosexual and psychosocial disorders, Peyronie's disease (acute and chronic), hormone health and substance use disorders.
Company Financials
EPS
PTPI has released its 2023 Q3 earnings. EPS was reported at -2.31, versus the expected 0.00, missing expectations. The chart below visualizes how PTPI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PTPI has released its 2024 Q4 earnings report, with revenue of 725.40K, reflecting a YoY change of 299.15%, and net profit of -9.27M, showing a YoY change of -3014.80%. The Sankey diagram below clearly presents PTPI’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
